Novel targeted therapy for treating ovarian cancer

Active Project Grant Awarded Last action

Award ID
R01CA266970
Recipient
Awarding agency
Obligated
$4,588,231

Award facts

Assistance listing
93.395 Cancer Treatment Research
Completion date 85% complete
Place of performance
San Antonio, TX 78229, USA

Award details come from USAspending.gov.

Description

As the agency reported it.

Abstract
Ovarian cancer (OCA) is the deadliest of all gynecologic cancers in the united states. Patients with OCA initially respond to standard combinations of surgical and cytotoxic therapy; however, nearly 90% will develop recurrence and inevitably succumb to chemotherapy-resistant disease. OCA stem cells are implicated in the tumor RE- initiation and therapy resistance. Lack of targeted therapies that promote apoptosis of tumor cells and eliminate cancer stem cells in OCA represents a critical barrier. The goal of this academic-industry partnership (AIP) grant application is to develop a novel targeted therapy for treating OCA. Through this AIP grant, we will establish a collaborative framework between the university of texas health at SAN antonio and evestra INC., a SAN antonio based biotech to create a novel targeted therapy for treating OCA. With evestra INC.'s expertise in developing novel small molecule inhibitors that disrupt protein-protein interactions, we have rationally designed and synthesized a first-in-class leukemia inhibitory factor receptor (lifr) inhibitor, EC359. Our preliminary studies have shown that EC359 reduces the growth of OCA cells with high potency, promote apoptosis, reduce stemness, sensitize therapy resistant OCA cells and has in vivo activity with favorable PK parameters. The objective of this AIP proposal is to synthesize EC359 in grams using GLP protocol, establish its mechanisms, identify biomarkers, conduct efficacy studies using PDX models, and perform off target screening studies that are needed to file the investigational new drug (IND) application to FDA. Our overarching hypothesis is that lifr signaling plays a critical role in OCA progression, and disruption of LIF/lifr signaling with small molecule inhibitor EC359 will have a therapeutic effect by promoting apoptosis of OCA cells, reducing stemness, and promoting anti-tumor immunity by altering the tumor microenvironment. Our AIP team is unique due to synergistic expertise in drug development, availability of GMP facility, experience with OCA biology, preclinical models and geographic proximity. In AIM1, we will evaluate translatability of EC359 by determining maximum tolerated dose, toxicity, biodistribution, in vivo efficacy using xenografts and PDX models and test the utility of EC359 in combination with standard of care chemotherapy. In aim 2, we will define EC359 mechanisms, establish molecular correlates of EC359 activity using unbiased genomic and proteomic approaches, define the role and mechanism by which EC359 reduces stemness and determine the role of EC359 in reprogramming the anti-OCA immunity, including macrophages, in syngeneic and humanized mouse models. In aim 3, we will synthesize EC359 using multi-gram scale, conduct metabolite studies, perform cardiovascular safety screens, and establish formulation and chemistry manufacturing controls. The studies proposed in this AIP proposal will establish a novel targeted therapy that will eliminate local tumor growth, reduce recurrence, and enhance the survival of OCA patients. EC359 could be utilized as a monotherapy, or in combination therapy or as a maintenance therapy, thus creating a new paradigm of novel targeted therapy for the treatment of OCA.

Transactions

Action Obligated Date
Amendment $619,437
Amendment $0
Amendment $0
Amendment $658,621
Amendment $639,397
Amendment $646,388
Amendment $646,388
Amendment $689,000
Original award $689,000

Subawards

Subrecipient Amount Awarded
Evestra, Inc. Subrecipient PI will organize their research activity as well coordinate extensive biological studies PE's lab. Subrecipient PI will spearhead formulation… $605,130

Quick answers

Who received award R01CA266970?

R01CA266970 was awarded to The University Of Texas Health Science Center At San Antonio by National Cancer Institute (National Institutes of Health) on August 1, 2022.

How much is award R01CA266970 worth?

$4,588,231 has been obligated on R01CA266970.

On GovTribe

See this award's full record

  • Every transaction and subaward
  • The recipient's other awards and teaming partners
  • Similar grant awards
  • Ask GovTribe AI about this award
Try for free Login